TITLE

Avandia, Risk of Congestive Heart Failure Significant Safety Risk

AUTHOR(S)
Elliott, William T.
PUB. DATE
July 2007
SOURCE
Travel Medicine Advisor;Jul2007, Vol. 17 Issue 7, Special section p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on several medications that were given warning for their effects or approved by the U.S. Food and Drug Administration (FDA) as of July 2007. Those given the black box warning include the rosiglitazone from GlaxoSmithKline and pioglitazone due to concerns over heart failure associated with the use of the said drugs for the treatment of type 2 diabetes. Rotigonine transdermal for the treatment of early stage idiopathic Parkinson's disease was approved by the agency.
ACCESSION #
25539198

 

Related Articles

  • First selective aldosterone-blocker now approved for CHF. LoBuono, Charlotte // Drug Topics;11/3/2003, Vol. 147 Issue 21, p28 

    Reports on the approval given by the U.S. Food and Drug Administration for the administration of eplerenone for treatment of congestive heart failure. Improvement of the survival of stable patients with left ventricular systolic dysfunction; Development of the drug Inspra from Pfizer Inc.;...

  • FDA Attempting To Overcome Major Roadblocks in Monitoring Drug Safety. Zielinski, Sarah L. // JNCI: Journal of the National Cancer Institute;6/15/2005, Vol. 97 Issue 12, p872 

    Reports that the U.S. Food and Drug Administration is attempting to overcome major roadblocks in monitoring drug safety. Developments which suggest that the landscape for drug safety monitoring is destined to improve; Number of people who die in the United States each year from adverse reactions...

  • Double-Standard Drugs. Clinton, Patrick // Pharmaceutical Executive;Dec2005, Vol. 25 Issue 12, p16 

    This article focuses on the drug approval standards in the U.S. Currently, the public attention is focused on drug safety, but the reality is that most industry critics are focusing on a far narrower issue: drugs that are approved because of having a favorable risk/benefit ratio in a particular...

  • Kyowa Hakko: non-approvable letter for Parkinson's treatment.  // PharmaWatch: CNS;Apr2008, Vol. 7 Issue 4, p4 

    The article reports on the issuance of non-approval letter by the U.S. Food and Drug Administration (FDA) for Kyowa Hakko's novel treatment for Parkinson's disease (PD) in the U.S. It is stated that the non-approval letter is a major hindrance to Kyowa Hakko but a good news for Eisai Co. Ltd. as...

  • FDA Approves First Race-Based Drug. Skloot, Rebecca // Discover;Jan2006, Vol. 27 Issue 1, p43 

    This article discusses issues regarding the approval of BiDil, a medicine designed to treat heart failure in African Americans by the U.S. Food and Drug Administration as of November 2005. Critics contend that the approval of the drug for use only by African Americans validates a genetic basis...

  • 'Sweeping' changes for the FDA proposed.  // Reactions Weekly;10/21/2006, Issue 1124, p3 

    The article reports that Curt D. Furberg of the Department of Public Health Services of Wake Forest University of Medicine at Winston-Salem and four of his colleagues called for changes to the U.S. Food and Drug Administration system for regulating drug safety in 2006. The group claims that the...

  • Washington Insider. THACKER, PAUL // Medical Marketing & Media;Oct2015, Vol. 50 Issue 10, p12 

    The article offers the author's insights on the approval made by the U.S. Food and Drug Administration (FDA) for the female sexual-dysfunction drug Addyi from Sprout Pharmaceuticals. Topics discussed include the clinical study of alcohol's side effects with the drug on men and women, the...

  • Neupro to Treat PD and RLS.  // Monthly Prescribing Reference;May2012, Vol. 28 Issue 5, pA-7 

    The article presents information that Neupro, rotigotine transdermal system, from UCB SA has been approved by the U.S. Food and Drug Administration (FDA) which is indicated for treatment of patients with Parkinson's disease (PD) and restless legs syndrome (RLS).

  • Advisory panel votes against Qnexa.  // OB/GYN Clinical Alert;Sep2010 Pharmacology, p2 

    The article discusses the disapproval of the weight-loss drug Qnexa by the U.S. Food and Drug Administration (FDA) due to its side effects such as depression, sleep disorders, and other cognitive disorders.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics